Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil

H W Sollinger1

  • 1Department of Surgery, University of Wisconsin, Madison, USA.

Kidney International. Supplement
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) effectively prevents and treats renal transplant rejection by inhibiting lymphocyte proliferation. Clinical trials show MMF is well-tolerated and improves renal function, offering a valuable alternative immunosuppressant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of ureteral stricture and treatment choice on long-term graft survival in kidney transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Is there any role for antithymocyte induction in renal transplantation?

Transplantation proceedings·2010
Same author

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.

Clinical transplantation·2009
Same author

Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
Same author

Stability of alemtuzumab for low-dose induction and test doses.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
Same journal

Effect of kidney disease on glucose handling (including genetic defects).

Kidney international. Supplement·2011
Same journal

Need for better diabetes treatment for improved renal outcome.

Kidney international. Supplement·2011
Same journal

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

Kidney international. Supplement·2011
Same journal

SGLT2 inhibitors: molecular design and potential differences in effect.

Kidney international. Supplement·2011
Same journal

Glucose handling by the kidney.

Kidney international. Supplement·2011
Same journal

Bone: from a reservoir of minerals to a regulator of energy metabolism.

Kidney international. Supplement·2011
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil (MMF) is a prodrug converted to mycophenolic acid (MPA), a potent inhibitor of de novo purine synthesis.
  • MPA selectively suppresses T and B lymphocyte proliferation, key components in transplant rejection.

Purpose of the Study:

  • To evaluate the efficacy and safety of MMF in preventing and treating renal allograft rejection.
  • To compare MMF-based immunosuppression with standard regimens.

Main Methods:

  • Animal studies demonstrated MMF's efficacy in prolonging allograft and xenograft survival.
  • Phase I clinical trials assessed MMF tolerability in renal transplant patients.
  • Multicenter studies evaluated MMF in combination with cyclosporine and prednisone for established rejection and as a primary immunosuppressant.

Related Experiment Videos

Main Results:

  • MMF was well-tolerated in renal transplant patients up to 3,500 mg/day for two years, with no dose-related adverse effects or observed nephrotoxicity, hepatotoxicity, or myelotoxicity.
  • In patients with biopsy-proven renal allograft rejection, MMF combined with standard immunosuppressants achieved successful rescue in 69% of cases.
  • A large multicenter trial showed MMF plus cyclosporine and prednisone was superior to azathioprine-based immunosuppression.

Conclusions:

  • MMF is effective and well-tolerated for preventing and treating acute renal allograft rejection.
  • MMF represents a valuable addition to the immunosuppressive agents available for renal transplantation.